68-1

72/98

) Miura Y, Horie S: The role of hormone therapy and chemotherapy in oligometastatic pros‑tate cancer. ESMO. Open, 2019; 4: e000471.) Ha Chung B, Horie S, Chiong E: The inci‑dence, mortality, and risk factors of prostate cancer in Asian men. Prostate Int, 2019; 7: 1-8.) De Marchi F, Araki M, Komatsu N: Molec‑ular features, prognosis, and novel treatment options for pediatric acute megakaryoblastic leukemia. Expert Rev Hematol, 2019; 12: 285- 293.) Suzuki Y, Mochizuki H, Oki M, Matsumoto M, Fukushima M, Yoshikawa Y, Nagasawa A, Takakura T, Shimoda N: Quantitative and Qualitative Analyses of the Clock Drawing Test in Fall and Non-Fall Patients with Alzheimer’s Disease. Dement Geriatr Cogn Dis Extra, 2019; 9: 381–388.) Ikeda A, Nishioka K, Meng H, Takanashi M, Hasegawa I, Inoshita T, Shiba-Fukushima K, Li Y, Yoshino H, Mori A, Okuzumi A, Yama‑guchi A, Nonaka R, Izawa N, Ishikawa KI, Saiki H, Morita M, Hasegawa M, Hasegawa K, Elahi M, Funayama M, Okano H, Akamatsu W, Imai Y, Hattori N: Mutations in CHCHD2 cause α-synuclein aggregation. Hum Mol Genet, 2019; 28: 3895-3911.) Sato K, Aita N, Hokari Y, Kitahara E, Tani M, Izawa N, Hatori K, Nakamura R, Sasaki F, Sekimoto S, Jo T, Oyama G, Hatano T, Shimo Y, Iwamuro H, Umemura A, Hattori N, Fuji‑wara T: Balance and Gait Improvements of Postoperative Rehabilitation in Patients with Parkinson’s Disease Treated with Subtha‑lamic Nucleus Deep Brain Stimulation (STN-DBS). Parkinsons Dis, 2019: 7104071.) Iijima M, Orimo S, Terashi H, Suzuki M, Hayashi A, Shimura H, Mitoma H, Kitagawa K, Okuma Y: Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson’s disease: A single-arm, open-label, prospec‑70nates Plasma Cells From a Renal Graft in Plasma Cell-Rich Acute Rejection. Trans‑plant Proc, 2019; 51: 1732-1738.〈Reviews〉 1 2Transfusion Medicine & Stem Cell Regulation〈Original Articles〉＊ 1) Maekawa T, Kato S, Kawamura T, Takada K, Sone T, Ogata H, Saito K, Izumi T, Nagao S, Takano K, Okada Y, Tachi N, Teramoto M, Horiuchi T, Hikota-Saga R, Endo-Umeda K, Uno S, Osawa Y, Kobayashi A, Kobayashi S, Sato K, Hashimoto M, Suzu S, Usuki K, Morishita S, Araki M, Makishima M, Komatsu N, Kimura F: Increased SLAMF7 high mono‑cytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab. Blood, 2019; 134: 814-825.) Inano T, Araki M, Morishita S, Imai M, Yasuda H, Nitta H, Ito M, Edahiro Y, Ochiai T, Misawa K, Fukuda Y, Ohsaka A, Komatsu N: JAK2 exon 12 mutation in myelodys‑plastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera. Br J Haematol, 2019; 187: e27-e31.) Edahiro Y, Araki M, Inano T, Ito M, Morishita S, Misawa K, Fukuda Y, Imai M, Ohsaka A, Komatsu N: Clinical and molecular features of patients with prefibrotic primary myelofi‑brosis previously diagnosed as having essen‑tial thrombocythemia in Japan. Eur J Haematol, 2019; 102: 516-520. 2 3＊ 4) Fukuda Y, Araki M, Yamamoto K, Morishita S, Inano T, Misawa K, Ochiai T, Edahiro Y, Imai M, Yasuda H, Gotoh A, Ohsaka A, Komatsu N: Evidence for prevention of renal dysfunction associated with primary myelofi‑brosis by cytoreductive therapy. Haemato‑logica, 2019; 104: e506-e509.) Araki M, Yang Y, Imai M, Mizukami Y, Kihara Y, Sunami Y, Masubuchi N, Edahiro 5Y, Hironaka Y, Osaga S, Ohsaka A, Komatsu N: Homomultimerization of mutant calretic‑ulin is a prerequisite for MPL binding and activation. Leukemia, 2019; 33: 122-131.) Nakamura Y, Okubo M, Furuta Y, Tokida M, Ichikawa K, Ohsaka A: Impact of CD34+ pre-counting and plerixafor on autologous peripheral blood stem cell collection in Japa‑nese university hospitals in eight years. Transfus Apher Sci, 2019; 58: 102664. 6〈Reviews〉 1Rehabilitation Medicine〈Original Articles〉 1 2 3 4